SEC Form 4 · accession 0000899243-15-002779
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathryn E Falberg
Director
Period of report
Aug 11, 2015
Accepted (ET)
Aug 11, 2015 · 11:33 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF2 | Aug 11, 2015 | P | 25,000 | $16.00 | A | 94,894 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reporting Person purchased an additional 25,000 shares of Issuer's common stock in connection with the initial public offering at the offering price of $16.00 per share.
- F2A portion of these shares is subject to a right of repurchase held by the Issuer.